SMaRT Replacement Therapy - OragenicsAlternative Names: A2JM
Latest Information Update: 16 Jul 2016
At a glance
- Originator Oragenics Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Dental caries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Dental-caries(In volunteers) in USA (Topical)
- 30 Mar 2011 Oragenics initiates enrolment in a phase I trial in Healthy volunteers in USA